While targeting early-phase cytokines gained only limited therapeutic effects, the administration of HMGB1 antagonists significantly improved the survival of systemic inflammatory response syndrome (SIRS) in rodents (77–79). The gene discussed is HMGB1; the disease is systemic inflammatory response syndrome.